Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG oncology RTOG trial 9704

Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG oncology RTOG trial 9704

Purpose: NRG Oncology RTOG 9704 was the first adjuvant trial to validate the prognostic value of postresection CA19-9 levels for survival in patients with pancreatic carcinoma. The data resulting from this study also provide information about predictors of recurrence that may be used to tailor indiv...

Full description

Bibliographic Details
Main Authors: William F. Regine, MD, Kathryn Winter, MS, Ross A. Abrams, MD, Howard Safran, MD, Ivan L. Kessel, MD, Yuhchyau Chen, MD, PhD, James A. Fugazzi, MD, Eric D. Donnelly, MD, Thomas A. DiPetrillo, MD, Samir Narayan, MD, John P. Plastaras, MD, Rakesh Gaur, MD, Guila Delouya, MD, John H. Suh, MD, Joshua E. Meyer, MD, Michael G. Haddock, MD, Mukund S. Didolkar, MD, Gilbert D.A. Padula, MD, David Johnson, MD, John P. Hoffman, MD, Christopher H. Crane, MD
Format: Article
Language:English
Published: Elsevier 2018-04-01
Series:Advances in Radiation Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S245210941830023X

Similar Items

Similar Items